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From March 1999 to March 2000, we conducted a prospective multicenter study of candidemia involving five
tertiary care hospitals from four countries in Latin America. Yeast isolates were identified by classical methods and
the antifungal susceptibility profile was determined according to the National Committee for Clinical Laboratory
Standards  microbroth assay method.
During a 12 month-period we were able to collect a total of 103 bloodstream isolates of  Candida spp. C. albicans
was the most frequently isolated species accounting for 42% of all isolates. Non-albicans Candida  species  strains
accounted for 58% of all episodes of candidemia and were mostly represented by C. tropicalis (24.2%) and C.
parapsilosis (21.3%). It is noteworthy that we were able to identify two cases of  C. lusitaniae from different institu-
tions. In our casuistic, non-albicans Candida  species  isolates related to candidemic episodes were susceptible to
fluconazole. Continuously surveillance programs are needed in order to identify possible changes in the species
distribution and antifungal susceptibility patterns of yeasts that may occurs after increasing the use of azoles in
Latin American hospitals.
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A progressive increase in the frequency of candidemia
has been observed, particularly among patients receiving
antibiotics, immunosuppressive therapy, or parenteral
nutrition, as well as among patients exposed to invasive
medical procedures such as intravascular catheter, hemo-
dialysis, and abdominal surgery (Lunel et al. 1999).
Despite Candida albicans is still considered the most
frequently isolated species of candidemic patients, the
emergence of non-albicans Candida species is clearly a
concern.  The resistance of non-C. albicans isolates to
currently available antifungal drugs represents a major
challenge for future empirical therapeutic and prophylac-
tic strategies (Krcmery & Barnes 2002).
  Due to the lack of information related to the epidemi-
ology of candidemia existing in our region, we conducted
a multicenter study to evaluate the species distribution
and antifungal susceptibility patterns of Candida spp.
bloodstream isolates in Latin American hospitals.
PATIENTS AND METHODS
Data collection and clinical specimens - From March
1999 to March 2000, we conducted a prospective
multicenter study of candidemia involving five tertiary
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care hospitals from four countries in Latin America: Hos-
pital Universitário de Maracaibo, Universidad del Zulia
(Luz) , Maracaibo, Venezuela, Hospital ¨ Cayetano Heredia¨,
Lima, Peru, Hospital de Clínicas ¨José de San Martín¨,
Universidad de Buenos Aires, Argentina, Instituto
Especializado em Pesquisa e Diagnóstico, Santa Casa de
Porto Alegre, Brazil and Hospital São Paulo, Escola Paulista
de Medicina, Universidade Federal de São Paulo, Brazil.
The centers were requested to send the isolated
strains to the reference laboratory (Laboratório Especial
de Micologia, Division of Infectious Diseases, Unifesp,
São Paulo, Brazil) for further identification and antifungal
susceptibility testing. In order to be included in this study
the patient must have had at least one blood culture posi-
tive for Candida spp., drawn from a peripheral vein, and
clinical evidence of sepsis.
Yeast identification procedures - The purity and vi-
ability of yeast original cultures were checked by plating
yeast colonies on CHROMagar Candida (CHROMagar
Microbiology Paris, France). C. albicans isolates were
identified if they exhibited green colonies on CHROMagar
Candida  and produced chlamydoconidia on corn meal-
Tween 80 agar. Non-albicans Candida  species  isolates
were identified on the basis of their micromorphology on
corn meal-Tween 80 agar and biochemical tests evaluated
by using the commercial system ID 32C, bioMérieux Marcy
l’Etoile, France  (Warren & Hazen 1995, Baumgartner et al.
1996).
In vitro susceptibility testing - Antifungal suscepti-
bility tests were performed by using the broth microdilution
assay according to the methodology recommended by
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the National Committee for Clinical Laboratory Standards
(NCCLS), document M-27 A2. The following antifungal
drugs, supplied by the manufacturers as pure standard
compounds, were tested: amphotericin B, fluconazole,
itraconazole and 5-flucytosine. Briefly, the medium used
was RPMI-1640, with L-glutamine, without bicarbonate,
and buffered at pH 7.0 with 0.165 M MOPS. The yeast
inoculum suspension was prepared by using a spectro-
photometer to obtain a final yeast concentration contain-
ing 0.5 - 2.5 x 103 cells/ml. The assays were incubated at
35°C for 48 h. The minimal inhibitory concentration (MIC)
for amphotericin B was considered the lowest tested con-
centration able to prevent visible growth. MIC for azoles
was considered as the lowest tested concentration with a
significant reduction (approximately 50%) in growth com-
pared to growth of a positive control (NCCLS 2002).
The breakpoints for azoles and 5-flucytosine MICs
were those suggested by the NCCLS M27-A2. Due to a
lack of consensus about the definition of MIC breakpoint
for amphotericin B, arbitrary values were established ac-
cording to values suggested by a previous study (Nguyen
et al. 1998). Isolates with MICs ≤ 8 µg/ml for fluconazole,
≤ 4 µg/ml for 5-flucytosine, ≤ 0.125 µg/ml for itraconazole,
and ≤ 1 µg/ml for amphotericin B were considered suscep-
tible. Isolates with MICs between 16 and 32 µg/ml for
fluconazole, and 0.25 to 0.5 µg/ml for itraconazole, were
considered to have reduced (dose-dependent) suscepti-
bility (DDS). MICs ≥ 64 µg/ml for fluconazole, ≥ 32 µg/ml
for 5-flucytosine, ≥ 1 µg/ml for itraconazole, and ≥ 2 µg/ml
for amphotericin B, were considered resistant (NCCLS
M27-A2).
RESULTS
During a 12 month-period we were able to collect a
total of 103 bloodstream isolates of Candida spp. C.
albicans was the most frequently isolated species ac-
counting for 42% of all isolates. As show in Table I, non-
albicans Candida  species  strains accounted for 58% of
all episodes of candidemia and were mostly represented
by C. tropicalis (24.2%) and C. parapsilosis (21.3%).
Table II shows MIC50 and MIC90 values exhibited by
the four antifungal drugs tested against the most fre-
quently isolated Candida spp. strains. C. albicans, C.
tropicalis and C. parapsilosis isolates were all suscep-
tible to fluconazole and amphotericin B.
Only one C. albicans isolate was resistant to 5-
flucytosine. Non-albicans Candida  species  isolates had
higher azoles MIC values than C. albicans isolates but
remained sensitive to low drug concentrations of ampho-
tericin B. C. glabrata isolates had fluconazole MIC50 and
MIC90 values of 2 and 4 µg/ml, respectively.
The two isolates of C. lusitaniae were susceptible to
amphotericin B (MICs of 0.125 and 0.5 µg/ml), itraconazole
(MICs of 0.03 and 0.015 µg/ml) and fluconazole (MICs of
0.25 and 0.5 µg/ml). Regarding to 5-flucytosine, one iso-
late was susceptible (MIC = 0.125 µg/ml) and the other
was intermediate (MIC = 8µg/ml).
Isolates of C. guilliermondii (3) were all susceptible
to amphotericin B (MICs of 0.05 and 1µg/ml), 5-flucytosine
(MICs of 0.125 µg/ml) and fluconazole (MICs of 4 and 8
µg/ml). Otherwise, all three isolates had susceptibility dose
dependent to itraconazole (MICs of 0.5 µg/ml).
TABLE I
Etiologic agents of 103 candidemic episodes
Etiologic agent N %
Candida   albicans 43 42
Candida  tropicalis 25    24.2
Candida  parapsilosis 22    21.3
Candida  glabrata 8     7.7
Candida  guilliermondii 3     2.9
Candida  lusitaniae 2     1.9
TABLE II
Antifungal susceptibility profile of 98 a Candida bloodstream isolates
   MIC (µg/ml)
Species (no.) Antifungal agent Range MIC 50 MIC 90
C. albicans Amphotericin B 0.125-1 0.5 0.5
(43) Flucytosine 0.125-64 0.125 0.125
Fluconazole 0.125-0.5 0.25 0.5
Itraconazole 0.007-0.03 0.015 0.03
C. tropicalis Amphotericin B 0.25-1 0.5 1
(25) Flucytosine 0.125 0.125 0.125
Fluconazole 0.125-0.5 0.25 0.5
Itraconazole 0.007-0.06 0.015 0.03
C. parapsilosis Amphotericin B 0.25-1 0.5 1
(22) Flucytosine 0.125-1 0.125 0.125
Fluconazole 0.125-2 0.5 2
Itraconazole 0.007-0.06 0.03 0.03
C. glabrata Amphotericin B 0.5-1 0.5 0.5
(8) Flucytosine 0.125 0.125 0.125
Fluconazole 2-8 2 4
Itraconazole 0.015-0.5 0.125 0.5
a: isolates of C. lusitaniae (2) and C. guilliermondii (3) were not included on this Table.
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DISCUSSION
Sandven (2000) reviewed 24 studies addressing epi-
sodes of candidemia in United States  tertiary care hospi-
tals and observed that the incidence of C. albicans iso-
lates ranged from 38.8% to 79.4% of all episodes. The
most prevalent non-albicans Candida  species reported
by the mentioned studies were C. glabrata, C. tropicalis
and C. parapsilosis.
Indeed, in most recent studies of candidemia conducted
in United States hospitals, C. glabrata accounted for 10%
to 21% of all candidemic episodes (Pfaller et al. 1998, 1999,
2000, 2001).
Studies from Canada showed a different picture from
the United States. In five out of six studies addressing the
epidemiology of candidemia, the incidence of C. albicans
isolates ranged from 53% to 74% and the non-albicans
Candida  species were correspondingly less prevalent.
The high prevalence of C. albicans in Canada resembles
the occurrence of this species in some European coun-
tries (Taylor et al. 1994, Karlowsky et al. 1997, Philips et al.
1997, Yamamura et al. 1999).
According to data from SENTRY and EORTC surveys,
performed between 1997 and 1999, the incidence of C.
albicans at European centers ranges from 49% (EORTC)
to 59% (SENTRY) of all episodes of candidemia (Viscoli et
al. 1999, Pfaller et al. 2001). Voss et al. (1996), after evaluat-
ing 626 episodes of candidemia in five Dutch’s hospital
observed that C. albicans isolates accounted for 60% of
all episodes. However, in the same study, the incidence of
non-albicans Candida  species   raised from 20 to 40%
between 1987 and 1995.
In the present study we observed that C. albicans is
the most frequent etiologic agent of candidemia in ter-
tiary care hospitals from four Latin American countries,
but non-albicans Candida  species responded for almost
60% of all cases. In contrast with most series of candidemia
from the United States and Europe, in which C. glabrata
has been increasingly reported, this species represented
only 7.5% of our candidemic episodes (Voss et al. 1996,
Abi-Said et al. 1997). The low incidence of infections by
primary azole resistant species of Candida may be related
to the limited use of fluconazole in our hospitals due to
cost considerations (Colombo et al. 1999). However,
considering the lack of information regarding to the con-
sume of antifungal drugs in Latin American Hospitals,
this hypothesis should be appropriately evaluated by
further investigations.
In our casuistic, C. tropicalis was the second most
frequently isolated species. The emergence of C. tropicalis
as an important etiologic agent of candidemia in north
hemisphere countries has been reported by several au-
thors (Nguyen et al. 1996, Pfaller et al. 2000,  2001).
Rodero et al. (1999) identified C. tropicalis as the sec-
ond most common isolate related to candidemic episodes
during a multicenter study performed with the participa-
tion of 12 medical centers located in Argentina, where 89
cases were evaluated. In accordance with our findings,
Colombo et al. (1999) reported that C. parapsilosis and C.
tropicalis were the two most common non-albicans Can-
dida species among 145 candidemic episodes documented
during a 18 month-period study including 6 different hos-
pitals in Brazil. Costa et al. (2000), after evaluating 86 con-
secutive episodes of candidemia documented in a single
tertiary care hospital from São Paulo, observed that C.
parapsilosis and C. tropicalis responded for most of all
non-albicans Candida isolates. Finally, Pfaller et al. (2001)
reported that in Latin American hospitals participating of
SENTRY, C. parapsilosis was the second most common
Candida species causing blood stream infections.
Most of our Candida bloodstream isolates were sus-
ceptible to all antifungal drug tested. However, we had
one strain of C. albicans and other of C. lusitaniae that
were resistant and intermediate, respectively, to 5-FC. Iso-
lates of C. albicans primarily resistant to 5-FC have been
identified in different clinical materials by several authors,
varying in frequency between 0% and 38% (Iwata 1992,
Barchiesi et al. 2000). The relationship between resistance
to 5-FC in C. albicans and serological type was investi-
gated by Drouhet et al. (1975), who reported that the per-
centage of 5FC-resistant strains isolated from patients in
Africa was higher than that recovered from patients in
Europe. They suggested that the high incidence of resis-
tance among the former strains was related to the pre-
dominance of serotype B isolates (Drouhet et al. 1975).
We were surprised by the low MIC values exhibited
by our C. glabrata isolates. Several publications from
north hemisphere countries have shown that C. glabrata
isolates usually exhibit high fluconazole MIC values
(Voss et al. 1996, Rex et al. 1997, Pfaller et al. 2001). Ac-
cording to SENTRY data, C. glabrata blood stream iso-
lates have MIC50 and MIC90 values ranging from 4 to 16
µg/ml and 16 to 32 µg/ml, respectively. In our series, all C.
glabrata isolates had MICs values ≤ 8. This aspect may
be also related to the higher use of fluconazole in Europe
and United States compared to Latin America.
It is noteworthy that we were able to identify two cases
of candidemia due to C. lusitaniae (one reported in Brazil
and the other in Argentina) and three cases of C.
guilliermondii. Both pathogens have been rarely reported
in different series of candidemia. Data from the Sentry
Program (Pfaller et al. 2001) did not mention any specific
data related to the identification of C. lusitaniae and C.
guilliermondii candidemic episodes.
Luzzati et al. (2000) were able to identify three cases of
invasive infection due to C. lusitaniae among 189
candidemic episodes reported in the University Hospital
of Verona, during the period of 1992 and 1997. In Latin
America, Colombo et al. (1999) reported only three cases
of candidemia due C. guilliermondii among 145 episodes
reported on six different tertiary care hospitals in Brazil.
Some authors advocate that C. lusitaniae isolates may
present innate resistance to amphotericin B (Pfaller et al.
1994, Hadfield et al. 1997). However, the amphotericin B
MIC results exhibited by both isolates of C. lusitaniae
from our series were 0.125 and 0.5 µg/ml respectively. This
aspect may be related to the limitations of the methodol-
ogy we used to recognize isolates truly resistant to am-
photericin B. The NCCLS methodology yields a range of
MICs that span only three to four twofold serial dilutions,
what make difficult a reliable discrimination between sus-
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ceptible and resistant isolates (Rex et al. 1995). Consider-
ing the mentioned limitation of the NCCLS methodology,
some authors have suggested to use the Etest with stan-
dardized RPMI medium supplemented with 2% glucose
as the most sensitive and reliable means for detecting
amphotericin B resistance (Wanger et al. 1995, Peyron et
al. 2001).
Although C. albicans continues to account for ap-
proximately one-half of all episodes of candidemia reported
worldwide, its frequency may vary widely from institu-
tion to institution. We were able to demonstrate that in
South America most non-albicans Candida  species are
represented by C. tropicalis and C. parapsilosis isolates
still susceptible to amphotericin B and fluconazole. How-
ever, continuously surveillance programs are needed in
order to identify possible changes in the species distribu-
tion and antifungal susceptibility patterns of yeasts, par-
ticularly after increasing the use of azoles in Latin Ameri-
can hospitals.
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